Clinical Guidelines for the Medical Management of Hepatitis C


  1. Kim WR. The burden of hepatitis C in the United States. Hepatology 2002; 36: S30–S34.
  2. Fried MW, Shiffman ML, Reddy R, et al. Peginterferon alfa-2a plus ribavirin for chronic HCV virus infection. N Engl J Med. 2002; 347:975–982.
  3. Afdhal NH. The natural history of hepatitis C. Semin Liver Dis. 2004; 24:3-8.
  4. Armstrong GL, Alter MJ, McQuillan GM, et al. The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. Hepatology 2000; 31:777-782.
  5. The Third National Health and Nutrition Examination Survey (NHANES III), 1988-94 subject/nhanes3.htm
  6. Alter MJ, Kruszon-Moran D, Nainan OV et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341:556-562.
  7. Curry MP, Hepatitis B and hepatitis C viruses in liver transplantation. Transplantation. 2004; 78:955-63.
  8. Leigh JP, Bowlus CL, Leistikow BN, Schenker MS. Costs of hepatitis C. Arch Int Med 2001; 161:2231-2237.
  9. Baillargeon J, Wu H, Kelley MJ, et al. Hepatitis C seroprevalence among newly incarcerated inmates in the Texas correctional system. Public Health. 2003; 117:43-8.
  10. Jonas M. Children with hepatitis C. Hepatology 2002, 36:S173-S178.
  11. NYS DOH and DOCS survey, unpublished data, 2002.
  12. Macalino GE, Vlahov D, Sanford-Colby S, et al. Prevalence and incidence of HIV, hepatitis B virus, and hepatitis C virus infections among males in Rhode Island prisons. Am J Public Health. 2004; 94:1218-23.
  13. Solomon L, Flynn C, Muck K, et al. Prevalence of HIV, syphilis, hepatitis B, and hepatitis C among entrants to Maryland correctional facilities. J Urban Health. 2004; 81:25-37.
  14. Stein JA, Nyamathi A. Correlates of hepatitis C virus infection in homeless men: a latent variable approach. Drug Alcohol Depend. 2004; 75:89-95.
  15. Nguyen MH, Keeffe EB. Epidemiology and treatment outcomes of patients with chronic hepatitis C and genotypes 4 to 9. Rev Gastroenterol Disord. 2004; 4:S14-21.
  16. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med. 2001; 345:41-52.
  17. Lehmann M, Meyer MF, Monazahian M, et al. High rate of spontaneous clearance of acute hepatitis C virus genotype 3 infection. J Med Virol. 2004; 73:387-91.
  18. Piasecki BA, Lewis JD, Reddy KR, et al. Influence of alcohol use, race, and viral coinfections on spontaneous HCV clearance in a US veteran population. Hepatology. 2004; 40:892-9.
  19. Centers for Disease Control and Prevention. Recommendations for the Prevention and Control of Hepatitis C Virus (HCV) Infection and HCV Related Disease. MMWR 1998; 47: 4-9.
  20. Schreiber GB, Busch MP, Kleinman SH, et. al. The risk of transfusion-transmitted viral infections. N Engl J Med. 1996;334:1685-1690.
  21. Diamond C, Thiede H, Perdue T, Viral hepatitis among young men who have sex with men: prevalence of infection, risk behaviors, and vaccination. Sex Trans Dis. 2003; 30:425-32.
  22. Strader DB, Wright T, Thomas DL, et. al. AASLD practice guidelines. diagnosis, management and treatment of hepatitis C. Hepatology, 2004; 39:1147-71.
  23. National Institutes of Health Consensus Development Conference Statement. Management of Hepatitis C: 2002 June 10-12, 2002. Hepatology. 2002; 36:S3-20.
  24. Thomas DL, Cannon RO, Shapiro CN, et. al. Hepatitis C, hepatitis B, and human immunodeficiency virus infections among non-intravenous drug-using patients attending clinics for sexually transmitted diseases. J Infect Dis. 1994; 169:990-5.
  25. Conry-Cantilena C, VanRaden M, Gibble J, et. al. Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection. N Engl J Med 1996; 334:1691-6.
  26. Sherman KE, Rouster SD, Chung RT, Rajicic N. Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US adult AIDS clinical trials group. Clin Infect Dis. 2002;34(6):831-837.
  27. Sulkowski M. Thomas DL. Hepatitis C in the HIV-infected Person. Annals Internal Medicine 2003; 138 (3):197-207.
  28. Batallan A., Faucher P., Poncelet C. et al. mother-to-child transmission of hepatitis C virus: recent news about the benefit of caesarean sections. Gynecol Obstet Fertil 2003; 31: 964-8.
  29. Ferrero S, Lungaro P, Bruzzone BM et al. Prospective study of mother-to-infant transmission of hepatitis C virus: a 10-year survey (1990-2000). Acta Obstet Gynecol Scand 2003; 82:229-34.
  30. Roberts EA., Yeung L. Maternal-infant transmission of hepatitis C virus infection. Hepatology 2002; 36: S106-13.
  31. Saez A., Losa M., Lo Iacono O. et al. Diagnostic and prognostic value of virologic tests in vertical transmission of hepatitis C virus infection: results of a large prospective study in pregnant women. Hepatogastroenterology 2004;51: 1104-8.
  32. Thomas DL, Factor SH, Kelen GD. Viral hepatitis in healthcare personnel at the Johns Hopkins Hospital. Arch in Med 1993; 153:170-120.
  33. Centers for Disease Control and Prevention. Updated U.S. Public Health Service Guidelines for the management of occupational exposures to HBV, HCV and HIV and recommendations for postexposure prophylaxis. MMWR 2001; 50:1-23.
  34. Esteban JL, Gomez j, Martell M, et al. Transmission of hepatitis C virus by a cardiac surgeon. N Engl J Med 1996;334:555-560.
  35. Duckworth GJ, Heptonstall J, Aitken C, et al. Transmission of hepatitis C virus from a surgeon to patient. Commun Dis Public Health 1999;2:188-192.
  36. New York State Department of Health. Policy Statement and Guidelines to Prevent Transmission of HIV and Hepatitis B Through Medical/Dental Procedures. August 1992.
  37. U.S. Preventive Services Task Force. Screening for hepatitis C in adults. Release Date: March 2004. uspstf/uspshepc.htm.
  38. Alter MJ. Epidemiology of hepatitis C. Hepatology 1997;26:62S-65S.
  39. Colin C, Lanoir D, Touzet S, et al. Sensitivity and specificity of third-generation hepatitis C virus antibody detection assays: an analysis of the literature. Journal of Viral Hepatitis 2001;8: 87-95.
  40. Alberti A, Bocacato S, Vario A, et al. Therapy of acute hepatitis C. Hepatology 2002;36: S195-S200.
  41. Gerlach JT, Diepolder HM, Zachoval R, et al. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology 2003;125: 80-88.
  42. Courouce AM, Le Marrec N, Girault A, et al. Anti-hepatitis C virus seroconversion in patients undergoing hemodialysis. Transfusion 1994;34: 790-795.
  43. Chamot E, Hirschel B, Wintsch J, et al. Loss of antibodies against hepatitis C virus in HIV-seropositive intravenous drug users. AIDS 1990; 4:1275-1277.
  44. Afdhal, NH and Nunes D. Evaluation of liver fibrosis: a concise review. Am J Gastroenterol 2004; 99: 1160-74.
  45. Poynard T, Imbert-Bismut, F Munteanu, M, et al. Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C. Comp Hepatol 2004; 3: 8-10.
  46. Poynard T, Munteanu, M Imbert-Bismut, F. Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C. Clin Chem 2004; 50: 1344-55.
  47. Goodgame B, Shaheen NJ, Galanko J, El- Serag HB. The risk of end stage liver disease and hepatocellular carcinoma among persons infected with hepatitis C virus: publication bias? Am J Gastroenterol 2003; 98(11): 2535-42.
  48. Dohmen K, Shigematsu H, and IK, Ishibashi, H. Trends in clinical characteristics, treatment and prognosis of hepatocellular carcinoma. Hepatogastroenterology 2003; 50(54): 1872-7.
  49. Sala M, Varela M, Bruix J. Selection of candidates with HCC for transplantation in the MELD era. Liver Transpl 2004;10: S4-9.
  50. Gebo S, El-Kamary SS, Bass E B. Screening tests for hepatocellular carcinoma in patients with chronic hepatitis C: a systematic review. Hepatology 2002; 36: S84-92.
  51. Hu KQ, Kyulo NL, Lim N, Elhazin B, Hillebrand DJ, Bock T, et al. Clinical significance of elevated alpha fetoprotein (AFP) in patients with chronic hepatitis C, but not hepatocellular carcinoma. Am J Gastroenterol 2004; (5): 860-5.
  52. Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 2004;130 (7): 417-22.
  53. Trevisani F, Cantarini MC, Labate AM, et al. Surveillance for hepatocellular carcinoma in elderly Italian patients with cirrhosis: effects on cancer staging and patient survival. Am J Gastroenterol 2004; 99(8): 1470-6.
  54. Lin OS, Keeffe EB, Sanders GD, Owens DK. Cost-effectiveness of screening for hepatocellular carcinoma in patients with cirrhosis due to chronic hepatitis C. Aliment Pharmacol Ther 200419(11): 1159-72.
  55. Zeuzum S, Diago M, Gane E, et al. International, multicenter, randomized controlled study for the treatment of patients with chronic hepatitis C and persistently normal ALT levels with peg-interferon alfa 2a and ribavirin. Hepatology 2003; 38: Abstract 106.
  56. Peg-Intron® [Package insert] Kenilworth NJ, Schering Plough Corporation, July 2002.
  57. Pegasys® [Package insert] Nutley, NJ Hoffman-La Roche Inc. October 2002.
  58. Sylvestre DL. Treating hepatitis C in methadone maintenance patients: an interim analysis. Drug Alcohol depend; 67:117-123.
  59. Zeuzem S, Feinman SV, Raseneck J, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. NEJM 2000;343: 1666-1672.
  60. Manns MP, McHutchison J, Gordon S et al. Peg interferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001;358: 958-965.
  61. Hadziyannis SJ, Sette H, Morgan TR, et al. Peginterferon alfa-2a (40KD) and ribavirin combination therapy in chronic hepatitis C: randomized study of the effect of treatment duration and ribavirin dose. Ann Int Med 2004;140: 346-355.
  62. Jeffers LJ, Cassidy W, Howell CD, et al. Peg-interferon alfa 2a and ribavirin in black Americans with chronic hepatitis C virus genotype 1. Hepatology 2004; 39: 1702-1708.
  63. Davis GL, Wong JB, McHutchison JG, et al. Early virological response to treatment with peginterferon alfa 2b plus ribavirin in patients with chronic hepatitis C.Hepatology 2003; 38:645-652.
  64. CoPegus® Package Insert. Nutley, NJ: Hoffmann-LaRoche; 2002.
  65. Torriani FJ, Rodriquez-Torres M, Rockstroh JK, et al. Peginterferon alfa 2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. NEJM 2004; 351:438-450.
  66. Jacobson IM, Ahmed F, Russo M, et al. Pegylated interferon alfa-2b plus ribavirin in patients with chronic hepatitis C: a trial in nonresponders to interferon monotherapy or combination therapy relapsers: final results. Gastroenterology 2003; 124: Abstract-540.
  67. Shiffman ML, Di Bisceglie AM, Lindsay KL, et al. Peginterferon alfa 2a and ribavirin in patients with chronic hepatitis C who failed prior treatment. Gastroenterology 2004; 126: 1015-1023.
  68. Delgado-Borrego A, Jonas MM. Treatment options for hepatitis C infection in children. Curr Treat Options Gastroenterology 2004. 7: 373-379.
  69. Poynard T, Regimbeau C, Myers RP, et al. Interferon for acute hepatitis C. Cochrane Database of Systemic Reviews 2002.
  70. Hoofnagle JH. Hepatitis C: the clinical spectrum of disease. Hepatology 1997; 26: 15S-20S.
  71. Jaekel E, Cornberg M, Wedemeyer H, et al. Treatment of acute hepatitis C with interferon alfa-2b. NEJM 2001; 345:1452-1457.
  72. Kamal SM, Madwar MA, He Q, et al. Peginterferon alfa compared with conventional interferon alfa and ribavirin combination therapy in asymptomatic acute hepatitis C: a randomized trial of treatment onset, duration and cost effectiveness. Hepatology 2004; 40: Abstract-37.
  73. Calleri G, Cariti G, Gaiottino F, et al. Three months course of Peg-interferon alfa-2b in acute HCV infection. Hepatology 2004;40: Abstract-38.
  74. Backmund M, Meyer K, Von Zielonka M, Eichenlaub. Treatment of hepatitis C infection in injection drug users. Hepatology. 2001; 34:188-93.
  75. Samet JH, Friedmann P, Saitz R. Benefits of linking primary medical care and substance abuse services. Arch Intern med 2001; 161: 85-91.
  76. Selwyn PA. The impact of HIV infection on medical services in drug abuse treatment programs. Journal of Substance Abuse Treatment 1996; 13(5):397-410.
  77. Litwin AH, Soloway I, Gourevitch M. Integrating hepatitis C services with methadone maintenance treatment: challenges and opportunities. CID. In press.
  78. Stancliff S. Drug Treatment and Harm Reduction. In: Finkelstein R, Ramos SE. Manual for primary care providers: effectively caring for active substance users. The New York Academy of Medicine 2002.
  79. Fireman M. Hepatitis C treatment and substance use disorders. Psychiatric Annals 2003; 33(6):402-8.
  80. Schiff ER. Hepatitis C and alcohol. Hepatology 1997; 26:39S-42S.
  81. Noda K, Yoshihara H, Suzuki K, et al. Progression of type C chronic hepatitis to liver cirrhosis and hepatocellular carcinoma – its relationship to alcohol drinking and the age of transfusion. Alcohol Clin Exp Res. 1996;20:95A-100A.
  82. Monto A, Patel K, Bostrom A, Pianko S, Pockros P, McHutchison JG, Wright TL. Risks of a range of alcohol intake on hepatitis C-related fibrosis. Hepatology. 2004; 39(3): 826-34.
  83. Lieber CS. Alcohol and hepatitis C. Alcohol Research and Health 2001; 25:245-54.
  84. Cromie SL, Jenkins PJ, Bowden DS, Dudley FJ. Chronic hepatitis C: effect of alcohol on hepatic activity and viral titre. J Hepatol. 1996; 25:821-6.
  85. Loguercio C, Di Pierro M, Marino MP, et al. Drinking habits of subjects with hepatiis C virus-related chronic liver disease: prevalence and effect on clinical, virological, and pathological aspects. Alcohol and Alcoholism 2000; 35:292-301.
  86. Zylberberg H, Fontaine H, Thepot V, Nalpas B, Brechot C, Pol S. Triggering of acute alcoholic hepatitis by alpha-interfron therapy. J Hepatol. 1999; 30:722-5.
  87. Straits-Troster KA, Sloan, Dominitz. Psychiatric and substance use disorder. Psychiatric Annals 2003; 33(6):362-6.
  88. Goldsmith JR, Mindrum G, Myaing M. Psychiatric assessment of patients with hepatitis C virus before initiating interferon treatment. Psychiatric Annals 2003; 33(6): 369-76.
  89. Summers J, Robinson R, Capps L, et al. The influence of HIV-related support groups on survival in women who lived with HIV. A pilot study. Psychosomatics 2000; 41(3):262-8.
  90. Kelly JA, Murphy DA, Bahr GR, et al. Outcome of cognitive-behavioral and support group brief therapies for depressed, HIV-infected persons. American Journal of Psychiatry 1993; 150(11):1679-86.
  91. Vargo S, Agronick G, O'Donnell L, Stueve A. Using peer recruitment and OraSure to increase HIV testing. American Journal of Public Health 2004; 94(1):29-31.
  92. Broadhead RS, Heckathorn DD, Altice FL, et al. Increasing drug users' adherence to HIV treatment: results of a peer-driven intervention feasibility study. Social Science and Medicine 2002; 55(2):235-46.
  93. Molassiotis A, Callaghan P, Twinn SF, Lam SW, Chung WY, Li CK. A pilot study of the effects of cognitive-behavioral group therapy and peer support/counseling in decreasing psychological distress and improving quality of life in Chinese patients with symptomatic HIV disease. AIDS Patient Care and STDs. 2002; 16(2):83-96.
  94. Fogarty LA, Heilig CM, Armstrong K, et al. Long-term effectiveness of peer-based intervention to promote condom and contraceptive use among HIV-positive and at-risk women. Public Health Reports 2001; 116(S1):103-19.
  95. Hawkins WE, Latkin C, Mandel W, Oziemkowska M. Do actions speak louder than words? Perceived peer influences on needle sharing and cleaning in a sample of injection drug users. AIDS Education and Prevention 1999; 11(2):122-31.
  96. Sylvestre DL, Loftis JM, Hauser P, et al. Co-occurring hepatitis C, substance use, and psychiatric illness: treatment issues and developing integrated models of care. Journal of Urban Health 2004; 81(4): 719-34.
  97. Pessione F, Degos F, Marcellin P, et al. Effect of alcohol consumption on serum hepatitis C virus RNA and histological lesions in chronic hepatitis C. Hepatology 1998;27:1717-22.
  98. Oshita M, Hayashi N, Kasahara A, et al. Increased serum hepatitis C virus RNA levels among alcoholic patients with chronic hepatitis C. Hepatology 1994;20:1115-20.
  99. Thomas DL. Hepatitis C and human immunodeficiency virus. Hepatology 2002; 36: S201-209.
  100. Fattovich G, et al. Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. European Concerted Action on Viral Hepatitis (EUROHEP). J Hepatol 1997;27: 201-5.
  101. Benhamou Y, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus co-infected patients. The Multivirc Group. Hepatology 1999; 30:1054-58.
  102. Poynard T, et al. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997; 349:825-32.
  103. Harris D, et al. The relationship of acute transfusion-associated hepatitis to the development of cirrhosis in the presence of alcohol abuse. Ann Intern Med 2001; 134: 120-4.
  104. Lucey MR, et al. Minimal criteria for placement of adults on the liver transplant waiting list: a report of a national conference organized by the American Society of Transplant Physicians and the American Association for the Study of Liver Diseases. Liver Transpl Surg 1997; 3:628-37.
  105. Arroyo V, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology 1996; 23:164-76.
  106. Liu LU, Schiano TD, Lau N, et al. Survival and risk of recidivism in methadone-dependent patients undergoing liver transplantation. Am J Transplant. 2003;3(10):1273-1277.
  107. Neff GW, et al. Orthotopic liver transplantation in patients with human immunodeficiency virus and end-stage liver disease. Liver Transpl 2003; 9:239-47.
  108. Rodriguez-Luna H, Douglas DD. Natural history of hepatitis C following liver transplantation. Curr Opin Infect Dis 2004; 17:363-71.
  109. Kamath PS, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001; 33:464-70.
  110. Saab S, Wang V. Recurrent hepatitis C following liver transplant: diagnosis, natural history, and therapeutic options. J Clin Gastroenterol 2003; 37:2:155-63.
  111. Riley TR 3rd, Smith JP. Ibuprofen-induced hepatotoxicity in patients with chronic hepatitis C: a case series. Am J Gastroenterol. 1998;93(9):1563-5.
  112. The National Center for Complementary and Alternative clinicaltrials/
  113. Terrault NA. Sexual activity as a risk factor for hepatitis C. Hepatology. 2002;36:S99-105.
  114. Hamid SS, Farooqui B, Rizvi Q, et al. Risk of transmission and features of hepatitis C after needlestick injuries. Infect Control Hosp Epi 1999; 20(1): 63-64.
  115. Mitsui T, Iwano K, Masuko K, et al. Hepatitis C virus infection in medical personnel after needlestick accident. Hepatology 1992; 16:1109-1114.
  116. Lanphear BP, Linnemann CC, Cannon, CG et al. Hepatitis C virus infection in healthcare workers: risk of exposure and infection. Infect Control Hosp Epi 1994; 15(12):745-750.
  117. Puro V, Petrosillo N, Ippolito G, et al. Italian study group on occupational risk of HIV and other bloodborne infections. Risk of hepatitis C seroconversion after occupational exposure in healthcare workers. Am J Infect Control 1995; 23:273-278.
  118. Sulkowski M. Thomas DL. Hepatitis C in the HIV-infected person. Annals Internal Medicine 2003; 138:197-207.

| Previous |